---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-081324"
form_type: "8-K"
ticker: "ONCO"
cik: "0001782107"
company_name: "Onconetix, Inc."
filed_at: "2023-10-10T23:59:59+00:00"
generated_at: "2026-06-10T02:37:46.691975+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Blue Water Biotech appoints Dr. Neil Campbell as CEO and Bruce Harmon as CFO effective October 4, 2023

## Summary
- Dr. Neil Campbell appointed President & CEO and board member; replaces prior plan for James Sapirstein as Interim Executive Chairman.
- Bruce Harmon appointed CFO, replacing Jon Garfield who resigned; Garfield receives $72,500 severance.
- Campbell receives $75,000 signing bonus, $475,000 base salary, option to purchase 3% of outstanding shares.
- Harmon receives $325,000 base salary, option to purchase 1% of outstanding shares.
- James Sapirstein appointed non-executive Chairman of the Board.

## SEC filing metadata
- accession: 0001213900-23-081324
- form_type: 8-K
- ticker: ONCO
- cik: 0001782107
- company_name: Onconetix, Inc.
- filed_at: 2023-10-10T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/ea186383-8k_bluewater.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-081324
- JSON: https://secwatch.observer/filing/0001213900-23-081324.json
- Plain text: https://secwatch.observer/filing/0001213900-23-081324.txt

## Key facts
- Executive change
  Jon Garfield resigned as Chief Financial Officer at Onconetix, Inc..
  - Action: resigned
  - Role: Chief Financial Officer
  source text: Effective as of October 4, 2023, Jon Garfield resigned as Chief Financial Officer of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm
- Executive change
  Neil Campbell was appointed as President and Chief Executive Officer at Onconetix, Inc..
  - Action: appointed
  - Role: President and Chief Executive Officer
  source text: appointed Dr. Neil Campbell, 63, as President and Chief Executive Officer of the Company and as a member of the Board of Directors
  evidence_url: https://www.sec.gov/Archives/edgar/data/1782107/000121390023081324/0001213900-23-081324-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.